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The chemokines (or chemotactic cytokines) are a large family of small,
secreted proteins that signal through cell surface G protein-coupled heptaheli-
cal chemokine receptors. They are best known for their ability to stimulate the
migration of cells, most notably white blood cells (leukocytes). Consequently,
chemokines play a central role in the development and homeostasis of the
immune system, and are involved in all protective or destructive immune and
inflammatory responses. Classically viewed as inducers of directed chemotactic
migration, it is now clear that chemokines can stimulate a variety of other
types of directed and undirected migratory behavior, such as haptotaxis,
chemokinesis, and haptokinesis, in addition to inducing cell arrest or adhe-
sion. However, chemokine receptors on leukocytes can do more than just
direct migration, and these molecules can also be expressed on, and regulate
the biology of, many nonleukocytic cell types. Chemokines are profoundly
affected by post-translational modification, by interaction with the extracellu-
lar matrix (ECM), and by binding to heptahelical ‘atypical’ chemokine recep-
tors that regulate chemokine localization and abundance. This guide gives a
broad overview of the chemokine and chemokine receptor families; summa-
rizes the complex physical interactions that occur in the chemokine network;
and, using specific examples, discusses general principles of chemokine func-
tion, focusing particularly on their ability to direct leukocyte migration.
Chemokines
Chemokines are defined by their primary amino acid
sequence and the arrangement of specific structurally
important cysteine residues within the mature protein.
These form disulfide bonds that maintain the structure
of the chemokine monomer, which consists of a central
three stranded b-sheet, an overlying C-terminal a-helix,
and a short unstructured N terminus that plays a criti-
cal role in receptor activation [1]. Variation in the pre-
cise configuration of the two cysteines closest to the N
terminus allows chemokines to be split into four
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subfamilies: CC, CXC, CX3C, and XC. In CC
chemokines, these cysteines are directly juxtaposed,
while CXC chemokines have a single variable amino
acid between them. The sole CX3C chemokine has
three amino acids between these two cysteines, while
XC chemokines, of which there are two forms in
humans and one in mice, lack the first and the third
cysteines of the motif. Large numbers of CC and CXC
chemokine genes have been defined in many species
(Fig. 1) [2]: not all are found in all species, or some-
times all members of a species; nonallelic isoforms
exist, such as CCL3L1 and CCL3 in humans [3,4] and
Ccl21a, Ccl21b, and Ccl21c in mice [5]; and allelic and
copy number variation creates considerable genetic
diversity that influences susceptibility to, and severity
of, a number of diseases [3,6,7].
Although chemokines were originally named accord-
ing to specific functions, a systematic nomenclature
was introduced in 2000 that includes a subfamily des-
ignation (i.e., CC, CXC, CX3C, or XC), followed by
the letter L (denoting ‘ligand’), and then a number
according to when the gene was first isolated [8,9].
Chemokines with the same name from different species
are often functional orthologues [2], although this is
not always the case: for example, human CCL8 binds
to the human CCR2 receptor, while mouse CCL8 is a
CCR8 ligand [10], and mouse CCL3 is functionally
more like human CCL3L1 than human CCL3 [11]. All
chemokines are produced with an N-terminal signal
peptide that is removed once it has directed the
chemokine into the endoplasmic reticulum for secre-
tion. Two chemokines, CX3CL1 and CXCL16, have
an extended C terminus containing a mucin-like stalk
and a transmembrane domain [12,13]. This holds these
chemokines on the cell surface but can be proteolyti-
cally cleaved to release the chemokine portion into the
extracellular space [14–18]. Other chemokines, such as
CCL6, CCL9, and CCL23, have an extended N termi-
nus that can be proteolytically removed to enhance
receptor activation capabilities [19]. An N-terminal
peptide cleaved off a CCL23 variant can activate for-
myl peptide receptor-like 1 (FPRL1), a G protein-
coupled receptor (GPCR) not classified as a cCKR
[20]. Alternatively spliced transcripts can generate che-
mokine variants: for example, six forms of human
CXCL12 have been described with different C termini
[21] and distinct biological properties [22,23].
GAGs, oligomerization, and post-
translational modification
The postsecretion activity and distribution of chemoki-
nes depends on how readily they become immobilized
on cell surfaces and ECM [24,25]. Glycosaminoglycans
(GAGs) are particularly important in this regard.
Their ability to bind chemokines influences chemo-
kine/receptor interactions; chemokine half-life in a tis-
sue or tissue compartment; how, and where, a
chemokine operates in vivo; and the type of cell move-
ment or adhesion it stimulates [24,25]. They are
Fig. 1. Mammalian chemokine receptors and their known interactions with chemokines and other key secreted, cell surface, and pathogen-
encoded molecules. Chemokines of the four subclasses (CCL, CXCL, CX3CL, and XCL) are arranged numerically in columns and represented
as numbered squares that are color-coded according to whether they are in humans and mice, humans only, or mice only (see Key). The
chemokine–chemokine ‘interactome’ [40] is not depicted. Chemokines are linked by lines to receptors that they are known to bind: yellow
boxes are atypical chemokine receptors (ACKRs) (previous names shown in parentheses); green boxes are conventional chemokine
receptors (cCKRs); and light green boxes show reported human cCKR variants generated by alternative splicing at the N terminus (CCR9,
CXCR3, CXCR4) or C terminus (CCR2) [69–74]. The color of the linking line (see Key) indicates whether the interaction likely exists in
humans only, mice only, or in humans and mice. Hashed black lines ending with a filled circle link chemokines with receptors they can
antagonize [119–126]. CXCL14 is reported to be a positive allosteric modulator of CXCR4 [344]. Chemokine receptors reported to form
heterodimers are linked with a black line [93–101,118]. Nonchemokine proteins in light pink boxes are able to activate the cCKR they are
joined to by a black line [89–92,102,347]. White boxes contain microbial proteins (red text) and other host extracellular/surface proteins
(black text; nonchemokine, nonchemokine receptor) that have been reported to interact, in the absence of chemokine, with the cCKR or
ACKR to which they are attached by a black line [32,92,102–117,147–152,167,233,264,345–348]. Note that cCKRs and ACKRs other than
those shown are known to be capable of binding HIV and/or gp120, but the role of these chemokine receptors during infection is uncertain.
CCL18 receptor PITPMN3 and CCL5 receptor GPR75 are also shown [127,348]. FPRL1 interacts with a peptide released proteolytically from
the N terminus of one form of CCL23 [20]. Gray boxes show drugs in clinical use: Maraviroc [143] and Plerixafor [237], antagonists of CCR5
and CXCR4, respectively; and Mogamulizumab, a humanized anti-CCR4 antibody approved for treatment of relapsed or refractory CCR4+
adult T-cell leukemia/lymphoma (CTCL) [349]. Definitions: ADM, adrenomedullin; ADRA1A/B, a1A/B-adrenoreceptors; C-18, cyclophilin-18 of
Toxoplasma gondii; CB2, cannabinoid receptor 2; DBP, Duffy binding protein of malarial parasites P. vivax and P knowlesi; DOR, delta-opioid
receptor; GluR1, component of the AMPA-type glutamate receptor; Glyco G, RSV G glycoprotein; gp120, the gp120 envelope protein of
HIV; GPR75, G protein-coupled receptor 75; HlgAB, Staphylococcus aureus c-Hemolysin AB; HMGB1, high mobility group box 1 protein;
KOR, kappa-opioid receptor; LukED, S. aureus leukotoxin ED; MIF, macrophage migration inhibitory factor; MOR, mu-opioid receptor;
PITPMN3, phosphatidylinositol transfer protein 3; PSMP, PC3-secreted microprotein; TCR, T-cell receptor; TSG-6, TNF-stimulated gene 6;
b2AR, b2-adrenergic receptor. Extended from previous reviews [64,350].
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essential for maintaining interstitial chemokine func-
tions and gradients [26–28] and for the presentation of
chemokines on endothelial surfaces, preventing them
being washed away by the blood and so allowing them
to drive leukocyte arrest and extravasation [29–31].
Some chemokines, such as CCL21, are very ‘sticky’
and become rapidly immobilized, while others, such as
CCL19, which activates the same receptor as CCL21,
likely diffuse more readily through tissues [27]. In
addition, mammalian proteins, including TSG-6, can
interfere with chemokine/GAG interactions to alter
chemokine distribution and function [32,33]. Targeted
disruption of chemokine/GAG interactions might have
therapeutic impact [34], as could GAG-based chemo-
kine-capturing hydrogels [35].
While chemokines are active as monomers, they also
form homodimers, heterodimers, and higher order
aggregates that can contain one or more chemokine spe-
cies, and this can be influenced by interactions with
GAGs [36–40]. The full chemokine ‘interactome’ reveals
complex and extensive interactions: human CXCL4 and
CCL5, for example, can each heterodimerize/oligomer-
ize with over 20 other chemokines from CC, CXC, and
XC subfamilies [40]. The structures formed rely on two
types of interfaces, referred to as CC- and CXC-type, in
which chemokine activity is typically enhanced and
inhibited, respectively [40]. Oligomerization clearly
influences how individual or mixtures of chemokines
combine to control leukocyte responses, and disrupting
specific interactions may have therapeutic potential
[1,25,39–41].
Chemokines are also profoundly affected by post-
translational modifications such as citrullination [42–
44], nitration/nitrosylation [45–47], and cleavage by
matrix metalloproteinases (MMPs), cathepsins, throm-
bin, plasmin, elastase, the dipeptidyl peptidase CD26,
and other proteases [48–50]. These changes can sub-
stantially modify chemokine activity. For example,
nitration of tyrosine residues in CCL2 by reactive
nitrogen species reduces the ability of this chemokine
to attract monocytes through its receptor CCR2 [45],
while arginine residues in a number of chemokines can
be converted into citrulline by the enzyme peptidy-
larginine deiminase: this reduces the chemotactic activ-
ity of CXCL8, CXCL10, and CXCL11, and prevents
conversion of CXCL8 into a more active shortened
form by interfering with thrombin- and plasmin-
mediated N-terminal trimming [42,44].
Proteases are key chemokine regulators. CD26-
mediated trimming of two amino acids off a chemo-
kine’s N terminus can, depending on the chemokine,
change receptor specificity, substantially alter receptor
affinity or convert agonists into antagonists [48]. Many
MMPs can also modify this part of certain chemoki-
nes, and the impact of these modifications depends on
the identity of the chemokine being studied. Thus,
MMP-mediated N-terminal trimming typically
enhances the activity of CXCR2 ligands, and of CC
chemokines with extended N-termini (CCL6, CCL9,
CCL23), while CXCL12 is inactivated by MMPs and
CCR2 ligands are converted into receptor antagonists
[50]. Proteolytic cleavage of the C terminus of
chemokines can dramatically alter ECM binding prop-
erties and diffusivity. For example, DC-mediated
cleavage of CCL21 removes the highly charged C ter-
minus that anchors it to the ECM, thereby releasing a
version of this key DC attractant that has much higher
diffusivity than the full-length protein [51]. This is
rather similar to the release of CX3CL1 and CXCL16
from cell surfaces that was mentioned above [14–18].
MMPs and other proteases can also act on the C ter-
minus of chemokines: for example, MMP processing
of the C terminus of CCL16 enhances its GAG-bind-
ing properties [52]. Proteases are also thought to help
create and modify interstitial chemokine gradients, and
have the capacity to degrade chemokines, or the ECM
to which they are bound, so are important in regulat-
ing chemokine half-life and distribution [49,53]. Con-
trolling protease regulation of chemokines could have
therapeutic application: for example, inhibiting CD26-
mediated cleavage of CXCL10 enhances tumor
immunotherapy in mouse models [54].
Chemokine receptors
There are two families of heptahelical surface mole-
cules that bind to chemokines: conventional chemo-
kine receptors (cCKRs) and atypical chemokine
receptors (ACKRs) (Fig. 1).
Conventional chemokine receptors
Chemokine-bound cCKRs typically transduce signals
through pertussis toxin-sensitive Gai G-proteins and b-
arrestins, ultimately leading to cell migration, adhesion
and/or a variety of other biological responses.
Chemokines are thought to initially tether to their cog-
nate cCKR via the extracellular loops and N terminus
of the receptor: the negative charge on these cCKR
domains can be increased by glycosylation, polysialyla-
tion, and/or the incorporation of sulphated tyrosine
residues. Sulphated tyrosines in the N terminus aid
HIV gp120 binding to CCR5 [55] and enhance chemo-
kine binding to CCR2 [56], CCR3 [57], CCR5 [55,58],
CCR8 [59], CXCR3 [60], CXCR4 [61], and CX3CR1
[62]. Polysialylation of CCR7 is essential for its
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activation by CCL21, appearing to release CCL21
from an auto-inhibited conformation [63].
Once a chemokine is tethered to a cCKR, its
unstructured N terminus enters the cCKR’s heptaheli-
cal bundle to induce a conformational change that is
translated into intracellular signals [64,65]. This classi-
cal two-site model of chemokine/receptor interaction is
probably oversimplistic, with recent studies suggesting
that the two supposedly independent ligand-binding
sites can be physically and allosterically linked, and
that additional interactions between chemokine and
receptor are likely to be involved in ensuring full
receptor activation [64]. The signaling pathways down-
stream of chemokine receptors are complex, and a
detailed description is beyond the scope of this review,
but they include, among others, heterotrimeric G-pro-
teins, b-arrestins, and JAK-STAT pathways [66,67].
There are currently 18 cCKRs named according to
the predominant type of chemokine they bind (i.e.,
CC, CXC, CX3C, or XC), followed by the letter R
(denoting ‘receptor’), and then a number reflecting the
order of their discovery (green boxes, Fig. 1). There
are 10 CCRs, 6 CXCRs, and a single CX3CR and
XCR. GPR35 has recently been identified as a
CXCL17 receptor and referred to as CXCR8 [68], but
may become known as CXCR7 now that the original
CXCR7 has been renamed ACKR3 [66]. Transcripts
encoding cCKRs can be subject to alternative splicing:
variants of CCR2, CCR9, CXCR3, and CXCR4 have
been reported with altered ligand-binding or signaling
properties [69–74]. Important detailed insights into
cCKR structure, chemokine binding, and mechanisms
of antagonism have come with the resolution of crystal
structures of CCR2, CCR5 CCR9, CXCR4, and
US28, a cytomegalovirus-encoded chemokine receptor,
and from other biophysical approaches [64,65,75–84].
Receptor specificity is complex: many chemokines
bind to multiple cCKRs, and some cCKRs have many
ligands (Fig. 1). This is prominent among chemokines/
cCKRs involved in inflammation, while those primar-
ily involved in homeostatic cell migration have only
one or two ligands that are faithful to a single cCKR.
Chemokines vary with respect to their affinity for a
particular cCKR, and biased signaling, or functional
selectivity, is emerging as a key feature of cCKRs,
such that the precise pathways activated by a cCKR
depend on which ligand it binds, and the cellular con-
text of that binding [85–88]. Currently, six cCKRs
have been reported to show biased signaling [88].
Moreover, some cCKRs can also be activated by non-
chemokine ligands: b-defensins can activate CCR6
[89]; the ‘alarmin’ high mobility group box 1 protein
(HMGB1) is emerging as a key CXCR4 ligand [90,91];
and cells expressing CXCR2 or CXCR4 migrate in
response to macrophage migration inhibitory factor
(MIF) (light pink boxes, Fig. 1) [92].
Like other GPCRs, cCKRs exist as homodimers.
They can also aggregate into higher order oligomers,
and form functionally distinct heterodimers with
ACKRs, other cCKRs, nonchemokine-binding GPCRs
(such as opioid receptors), and other membrane
proteins (white boxes, Fig. 1) [87,93–118]. Some
chemokines can act as natural cCKR antagonists
(Fig. 1) [119–126]. Phosphatidylinositol transfer pro-
tein (PITPMN3), a non-GPCR with six transmem-
brane domains, is reported to be a functional receptor
for CCL18 in the context of tumor cell invasion [127],
although, more conventionally, CCL18 also binds to,
and directs leukocyte migration through, the cCKR
CCR8 [128].
The striking receptor/ligand promiscuity common in
the chemokine network most likely evolved to combat
microbial subversion by building robustness into
leukocyte responses during infection. Many viral gen-
omes carry genes encoding chemokines, chemokine-
binding proteins, and/or heptahelical receptors capable
of interfering with parts of the host chemokine system;
or they contain genes encoding chemokines and/or
chemokine receptors that activate, or are activated by,
host cCKRs or chemokines [129]. The saliva of blood-
sucking ticks contains chemokine-binding proteins
thought to suppress inflammation at the bite site [130–
132]. Human immunodeficiency virus (HIV) has
evolved to exploit cCKRs: CXCR4, and particularly
CCR5, are vital coreceptors mediating HIV entry into
cells and can dock to the HIV gp120 envelope protein
after it has bound CD4 [133–139]. The ligands for
these cCKRs block HIV entry into cells by steric hin-
drance or cCKR down-regulation, and genetic varia-
tion in genes encoding CXCL12, CCR5, and CCR5
ligands profoundly influences susceptibility to HIV
infection and the rate of progression to AIDS
[3,7,140]. Most notably, homozygosity for the non-
functional D32-CCR5 allele profoundly protects
against HIV infection, while D32-CCR5 heterozygosity
is associated with slowed progression to AIDS in most
cohorts of HIV-infected people [7,140–142]. CCR5
antagonist Maraviroc [143] is now used clinically,
alongside other drugs, to delay progression to AIDS in
HIV-positive patients, and there was considerable pub-
licity when transplantation of HLA-matched stem cells
from D32-CCR5 homozygotes proved very effective in
treating an HIV-infected patient [144]. However, some
caution is required because after infection with West
Nile Virus, D32-CCR5 homozygosity increases the like-
lihood of developing encephalitic symptoms, and of
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dying from the infection [145], most likely due to
defects in the trafficking of protective leukocytes into
the brain [146].
Other pathogens target chemokine receptors. Some
malarial parasites use ACKR1 to enter erythrocytes (see
below); cyclophilin-18 from Toxoplasma gondii binds to,
and signals through, CCR5 [147]; respiratory syncytial
virus (RSV) uses it’s glycoprotein G to infect a subset of
B cells through CX3CR1 [148]; and Staphylococcus
aureus leukotoxin ED (LukED) and c-hemolysin AB
toxin (HlgAB) target ACKR1 and various cCKRs to
lyse erythrocytes and kill leukocytes, respectively
[149–152]. These interactions have important conse-
quences for the pathogenicity of these microorganisms.
Atypical chemokine receptors
Atypical chemokine receptors, of which there are four
(yellow boxes, Fig. 1), are structurally related to
cCKRs but do not couple to many, if any, of the sig-
nal transduction pathways activated by cCKRs
[66,153]. Many publications report signaling and asso-
ciated biological responses via ACKR3, but it remains
unclear and/or controversial whether ACKR1, 2, and
4 can transduce signals at all after chemokine binding
[154]. This may be in part due to the absence, or mod-
ification, of appropriate signaling motifs on the intra-
cellular surface of ACKRs, such as the canonical
DRYLAIV motif present in the second intracellular
loop of cCKRs [153]. However, ACKRs bind
chemokines with high affinity [154], and, like cCKRs,
use sulphated tyrosine residues to enhance chemokine
binding [155,156].
All ACKRs appear to be involved in regulating che-
mokine localization, distribution, and abundance,
thereby indirectly controlling interactions between
chemokines and cCKRs [153]. For example, ACKR1
transports chemokines across endothelial cells for pre-
sentation to blood-borne leukocytes [157,158], and, on
erythrocytes, ACKR1 buffers chemokine abundance in
the blood [159–163]: this likely prevents cCKRs on cir-
culating leukocytes being inappropriately desensitized
by exposure to excess chemokine. Interestingly,
ACKR1 can regulate hemopoietic stem and progenitor
cells in the bone marrow (BM), and control neutrophil
phenotype/abundance in the blood, although the
underpinning molecular mechanisms remain unclear
[164,165]. ACKR1 is pirated by malarial parasites
Plasmodium vivax and Plasmodium knowlesi, which use
their Duffy binding protein (DBP) to engage ACKR1
and gain entry into erythrocytes [166–168]. Genetic
variation in ACKR1 profoundly influences susceptibil-
ity to infection by these parasites, and the complete
loss of ACKR1 from erythrocytes is very common in
sub-Saharan African populations [169,170]. The
absence of ACKR1 from erythrocytes also appears to
cause benign ethnic neutropenia [165,171,172] and may
influence HIV infection by leading to CCR5 ligand
dysregulation or loss of ACKR1-mediated HIV pre-
sentation [173,174], although this was not borne out in
other studies [175–178].
ACKR2 is a well-characterized chemokine scav-
enger. It constitutively shuttles to and from cell sur-
faces without needing chemokine-induced signals to do
so, and internalizes any chemokines it encounters while
exposed to the extracellular space [179,180]. Internal-
ized chemokine is dislodged from ACKR2 and
degraded [179,180]. ACKR2 serves key regulatory
functions in developing mammary gland and on lym-
phatic endothelial cells (LECs), innate-like B cells, and
placental trophoblasts [181–190]. ACKR3 is instru-
mental in controlling the CXCL12-CXCR4 axis, either
by scavenging CXCL12 or by heterodimerizing with,
and regulating the function of, CXCR4 [99,100,191–
200]. ACKR4-mediated scavenging of CCL19 and/or
CCL21 can regulate CCR7-dependent dendritic cell
migration and adaptive immune responses [201–204],
and roles for this ACKR have been reported in the
thymus [205,206]. cCKRs can also remove extracellular
chemokines, albeit less efficiently than ACKRs, and
internalization of surface chemokine/cCKR complexes
is a key aspect of cCKR regulation. Consequently,
mice in which a cCKR gene has been deleted can have
elevated levels of the chemokine(s) that normally bind
that cCKR [207]. Thus, chemokine regulation by
receptor-mediated internalization is not limited to
ACKRs.
The function of the chemokine
network
By far the most studied function of the chemokine net-
work is cell migration, particularly of leukocytes.
However, the biological activity of chemokines is by
no means limited to this function or to these cell types
(Fig. 2). As recently reviewed elsewhere [208], a wide
variety of other biological processes can be induced by
the activation of cCKRs on leukocytes, including pro-
liferation, survival, differentiation, cytokine produc-
tion, degranulation, and respiratory burst (Fig. 2).
Moreover, several chemokines have direct antimicro-
bial activity [209]. In addition, many nonleukocytic cell
types, including neurons, astrocytes, epithelial cells,
mesenchymal cells, and endothelial cells, can express
cCKRs and respond in a wide variety of ways to
chemokines [210–216]. For example, many chemokines
6 The FEBS Journal (2018) ª 2018 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
A guide to chemokines and their receptors C. E. Hughes and R. J. B. Nibbs
directly regulate angiogenesis, with distinct subsets
showing negative or positive angiogenic activity
[214,215]. Interestingly, cancer cells of nonleukocytic
origin can evolve to express cCKRs and respond to
chemokines: this can encourage local invasion, spread
to draining lymph nodes, and the metastatic seeding of
distant tissues [217,218]. Cell movement is the domi-
nant biological process regulated by chemokines and
their receptors, and many different types of cell move-
ment that have been reported fall under chemokine
control, including chemotaxis (often seen as the classic
chemokine-driven form of migration) and also encom-
passing haptotaxis, chemokinesis, haptokinesis and
transcellular migration. In some contexts, chemokines
can direct the migration of groups of cells (referred to
as collective migration) [219–221], or stimulate cell
adhesion, causing cell movement to stop. There are
also reports of cells moving down, rather than up, che-
mokine concentration gradients, i.e., away from the
chemokine source, a process termed chemorepulsion or
chemofugetaxis [222–224] (Fig. 2).
Leukocyte migration is of critical immunological
importance. Leukocytes must be in the right place at
the right time so that their immunological functions
can be appropriately localized and directed. Immune
surveillance requires the continuous trafficking of
leukocytes out of BM and into, within, and out of the
other tissues of the body. When tissues become dam-
aged and/or infected, the rapid recruitment of innate
immune cells is essential to kill pathogens, prevent
microbial dissemination, drive inflammation, and help
repair damage. The elaboration of a regulated adaptive
immune response, and the subsequent development of
immune memory, depends on further carefully chore-
ographed leukocyte migratory processes. Chemokines
are of central importance in all these processes driving
leukocytes into and out of blood and lymphatic ves-
sels, and directing their interstitial movement and posi-
tioning. Without chemokine-directed leukocyte
migration, immune tolerance breaks down, immuno-
surveillance fails, and protective immune responses are
compromised. However, chemokine-directed leukocyte
migration also contributes to diseases that have an
immune or inflammatory component including autoim-
munity, allergy, chronic inflammatory disease,
atherosclerosis, cancer, and many others. In this con-
text, interfering with chemokine-directed leukocyte
migration has therapeutic potential.
The size of the chemokine and cCKR families
enables leukocyte recruitment to be tailored to fit the
immunological needs of tissues. While many molecules
are required for cells to be able to leave the blood-
stream and navigate within tissues [29,225], typically
the expression of a particular cCKR enables a leuko-
cyte to migrate in response to that receptor’s ligands.
Figure 3 shows the expression of chemokine receptor
genes in a variety of leukocytes and stromal cells in
mice. These data are consistent with protein expression
data, and broadly conserved in humans. Some cCKR
genes, such as Ccr3, Cxcr1, and Cxcr2, clearly show
highly restricted patterns of expression, while others,
particularly Cxcr4, are more uniformly expressed.
ACKRs are mainly limited to stromal cells, although
Ackr1 is expressed by erythrocyte precursors (not
shown in Fig. 3) [164] and the other ACKRs are tran-
scribed in discrete subsets of B cells [99,189,226].
Leukocyte activation can change cCKR expression
profiles dramatically to couple changes in immunologi-
cal function with switches in migratory potential. This
makes sense if the new function requires the cell to
localize to a different tissue or microanatomical niche.
This is discussed below in the context of CD4+ T cells.
Likewise, distinct tissues or tissue domains express
specific profiles of chemokines under homeostatic con-
ditions (Fig. 4), and this changes with infection or
damage when the immunological requirements of the
tissue change. For example, in mice, CCL25 is consti-
tutively expressed in the small intestine [227], while
mouse skin makes substantial quantities of CXCL14,
CCL8 ,and CCL27 [10,228,229], but when these or
other tissues are damaged, inflamed or infected, large
numbers of inflammatory chemokines are induced to
direct the rapid recruitment of innate immune cells
and the subsequent homing of effector T cells.
Development, homeostasis, and
immune surveillance
Only the CXCL12/CXCR4/ACKR3 node of the che-
mokine network is necessary for life. CXCL12, the
most primitive chemokine, has been strongly conserved
through evolution. Acting through CXCR4 and regu-
lated by ACKR3, CXCL12 is critical for the develop-
ment of the heart, brain, vascular system,
hematopoietic system, germ cells, and, in fish, the lat-
eral line [99,191–200,230–232]. Deletion of Cxcl12 or
Cxcr4 in mice results in a variety of developmental
abnormalities and death in utero [230–232]. Ackr3 defi-
ciency has a similar outcome, although some Ackr3-
deficient mice survive until birth [99,193,194]. ACKR3-
mediated scavenging of adrenomedullin (ADM) may
be significant during heart and lymphatic vasculature
development [233]. Many indispensable functions for
CXCL12 have been defined in the adult, including its
role in hematopoiesis where it is a key component of
the niche that supports hematopoietic stem cells
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(HSCs) in the BM [234–236]. Blocking CXCR4 func-
tion liberates HSCs from the BM, and CXCR4 antag-
onist AMD3100 (Plerixafor) is used clinically to
mobilize HSCs for collection from peripheral blood
prior to autologous stem cell transplantation [237].
Autosomal dominant mutations in CXCR4 are
responsible for WHIM syndrome (warts, hypogamma-
globulinemia, immunodeficiency, myelokathexis syn-
drome), a rare genetic disease in which patients have
IgG antibody deficiency, neutropenia (due to retention
of neutrophils in the BM), and increased susceptibility
to bacterial and viral infections (including human
papillomaviruses, which causes warts) [238]. The muta-
tions truncate or mutate the C terminus of CXCR4
[238,239], disrupting negative regulatory domains and
enhancing receptor activity [240,241]. Plerixafor shows
promise as a therapeutic [242] and there is a remark-
able report that chromothripsis, a process in which
chromosomes undergo extensive rearrangements and
deletions, spontaneously cured a WHIM syndrome
patient [243].
CXCR5 and CCR7 serve key developmental roles
by regulating the homing of lymphoid tissue inducer
(LTi) cells. During embryonic life, these cells migrate
out of the blood into sites where secondary lymphoid
tissues will form. This is critical for the development
of lymph nodes and Peyer’s patches, and mice defec-
tive in both the CXCR5/CXCL13 and CCR7/CCL21
axes lack Peyer’s patches and virtually all lymph nodes
[244–249].
Some cCKRs serve well-defined homeostatic tissue-
specific functions driven by the constitutive expression
of their ligands under steady-state conditions (Fig. 4).
For example, several chemokine receptors, including
CCR4, CCR9, and particularly CCR7, contribute to
T-cell development by enabling cells to enter and
navigate within the thymus [250–260]. This facilitates
the selection and differentiation processes that are
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essential for central tolerance, the generation of the
na€ıve T-cell repertoire, and natural regulatory T-cell
(nTreg) formation. Deletion of Ccr7 or its ligands
disrupts thymocyte trafficking in mice creating an
aberrant na€ıve T-cell repertoire that drives autoimmu-
nity [252–255,261]. CCR7 is also essential for leuko-
cyte entry into lymph nodes and other secondary
lymphoid tissues [262], with recent reports describing
circadian fluctuations in the CCL21/CCR7 axis and
lymphocyte trafficking into lymph nodes controlled
by adrenergic nerves [263–265]. CCR7 facilitates lym-
phocyte recruitment from blood [266]; stimulates
intranodal T-cell motility [267–269] and retention
[264,270]; directs dendritic cells (DCs) [27] and other
leukocytes [271,272] into tissue lymphatic vessels
along CCL21 gradients [27] aided by DC-induced
CCL21 secretion from LECs [273]; mediates intralym-
phatic crawling [274,275]; and allows DCs to enter
the lymph node parenchyma from the subcapsular
sinus [276]. Thus, in addition to directing central
tolerance, CCR7 is essential for peripheral tolerance
and the initiation of adaptive immune responses
[262].
There are many other instances of chemokine-driven
homeostatic leukocyte trafficking. For example, CCR2
is required for Ly6Chi monocyte release from BM
[277]; CCR3 controls steady-state eosinophil distribu-
tion [278]; CXCR2 and CXCR4 direct neutrophil
egress from, and return to, the BM [279,280]; mono-
cytes use CX3CR1 to patrol blood vessel walls [281];
and CCR9 regulates plasmacytoid DC and intraepithe-
lial cd T-cell abundance in the small intestine
[258,282]. B cells are specifically directed to lymphoid
tissue follicles by CXCR5 [244,245], which also
controls marginal zone B cell and B1 B cell migration
in mouse spleen and body cavities, respectively
[283,284].
Therefore, chemokine-driven cell migration serves
critical developmental functions; ensures immunologi-
cal tolerance is established and maintained; enables
antigen-specific lymphocytes to enter and survey anti-
gen-presenting cells in lymphoid tissue; and distributes
leukocytes around the body so they are appropriately
placed to respond to immunological challenge.
Infection, inflammation, and
immunopathology
Chemokines, along with an array of other proteins,
peptides, lipids, and microbial products, direct leuko-
cyte recruitment into infected or damaged tissues
[66,285]. Many chemokines are highly inducible and
produced in large quantities in response to a broad
array of infectious and inflammatory stimuli. Leuko-
cytes recruited by chemokines early to damaged or
infected tissues can produce other chemokines that
contribute to the next wave of leukocyte homing
[286,287]. Chemokines are produced by many diseased
tissues, including those affected by autoimmunity
[288–290], allergy [291], Alzheimer’s disease [292],
chronic inflammatory disease [293], cardiovascular dis-
ease [294], and cancer [295]. These inflammatory che-
mokine profiles typically include those chemokines
that bind to the promiscuous cCKRs and ACKRs
(i.e., CCR1, CCR2, CCR3, CCR5, CXCR1, CXCR2,
CXCR3, ACKR1, and ACKR2) (Fig. 1), but other
chemokines can also be induced, and the precise che-
mokine profile in a given tissue will depend on the
exact nature of the inducing stimuli, the phase of the
response, and the genetics of the chemokine network
in the affected individual.
Inflammatory chemokine abundance, distribution,
and activity will be controlled by their interactions
with ECM, proteases, and other proteins within the
tissue, and by scavenging via cCKRs and ACKRs,
particularly ACKR1 and ACKR2. Inflammatory
chemokines make a major contribution to the recruit-
ment of leukocyte populations required to meet the
immunological needs of affected tissues, and will regu-
late any nonleukocyte tissue cells (epithelial, mesenchy-
mal, and/or endothelial) constitutively or inducibly
expressing cCKRs. Many microbes have evolved to
interfere with inflammatory chemokines and cCKRs,
leading to an ‘arms race’ that has built robustness and
Fig. 4. Expression of chemokine genes in selected mouse tissues under steady-state conditions. By examining graphs generated on The
Immunological Genome Project website (www.immgen.org) [351] using their transcriptomic data, the expression of each chemokine, in
each of the tissues shown (left hand column), was assigned to one of the seven color-coded ‘Expression Level Categories’ indicated in the
key in the center of the Figure. Expression in the central nervous system (CNS) was estimated by examining ImmGen data on numerous
component parts of the CNS. Expression by lymphocytes was included to help indicate whether chemokine expression by secondary
lymphoid organs could be attributed to expression by lymphocytes, the dominant cell type in these organs. It was estimated by examining
ImmGen data on B cells, CD4+ T cells, and CD8+ T cells. It should be noted that the function of a chemokine in a tissue will depend of
where it is expressed: for example, expression by blood vessel endothelial cells may enable leukocyte recruitment from the blood, while
their presence elsewhere might help direct leukocytes to specific microanatomical niches, or encourage departure via lymphatic vessels.
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redundancy into this part of the chemokine network.
Nonetheless, individual cCKRs serve indispensable
roles in a variety of contexts, and there is a vast litera-
ture describing how deleting, inhibiting, or blocking
individual cCKRs or ACKRs impacts on a wide vari-
ety of experimentally induced immune and inflamma-
tory responses, and modifies pathology in a diverse
array of animal models of human disease. This under-
standably led to the development of small molecule
cCKR antagonists to trial in patients with immune or
inflammatory disease [66]. However, despite consider-
able efforts, to our knowledge, no effective therapeu-
tics for these diseases have yet emerged, and while the
in-built robustness of the inflammatory chemokine net-
work has no doubt been a contributing factor, several
other likely reasons have been proposed and discussed
[296]. Nonetheless, clinical trials using chemokine
receptor antagonists, or other therapeutic approaches
that target or exploit chemokines, continue to take
place.
Chemokine receptor switching
Changes in leukocyte function are intimately associ-
ated with switches in cCKR expression. For example,
DC trafficking from tissues to draining lymph nodes
requires inflammatory cCKRs to be lost and CCR7 to
be switched on [262,297–299]. cCKR switching is also
prominent during CD4+ and CD8+ T-cell activation
and differentiation, and cCKRs are reported to
directly contribute to T-cell costimulation [300,301].
When CD4+ T cells encounter antigen, they can differ-
entiate into one of many functionally distinct T cell
types, including effector T cells (Th1, Th2, and Th17),
follicular T cells (Tfh and Tfr), induced regulatory T
cells (iTreg), and memory T cells (Tcm and Tem).
These cells have discrete immunological functions that
require specific migratory behaviors so they need to
express particular cCKR profiles. Th1 cells typically
express CCR5 and CXCR3 (as do many recently-acti-
vated CD8+ T cells); Th2 cells preferentially display
CCR3 and CCR4; and Th17 are often CCR6+ [302–
308]. This enables these effector T cells to home to
infected or inflamed tissues where they contribute to
microbial clearance and tissue repair. In contrast, Tfh
and Tfr cells control activated B cells so need to enter
B cell follicles in lymphoid tissues: they achieve this by
up-regulating CXCR5 expression [309–314]. Likewise,
during viral infection, CXCR5 is expressed by some
activated cytotoxic T cells so that they enter follicles
to attack virally infected Tfh and B cells [315].
Antigen-experienced T cells can be imprinted with
cCKRs that enable them to selectively home to specific
tissues. T cells that encounter antigen in mesenteric
lymph nodes draining the small intestine will often
express CCR9 to enable homing back to the small
intestine [316–319]. This depends on the specialization
of DC and stromal cells in the mesenteric lymph nodes
and production of retinoic acid from dietary vitamin
A [319–324]. Likewise, T cells activated in skin-drain-
ing lymph nodes typically express CCR4, CCR8, or
CCR10 to enable homing to the skin: this may depend
on skin-derived vitamin D3 and keratinocyte products
[10,229,325–329]. In contrast, central memory CD4+
and CD8+ T cells (Tcm), like na€ıve T cells, traffic
through secondary lymphoid organs using CCR7,
while other memory T cells lose CCR7 and express
cCKRs that enable them to home to nonlymphoid tis-
sues [330]. These memory cells can remain resident in
the nonlymphoid tissue or home back to lymph nodes
by up-regulating CCR7 [271,272]. In addition, recent
work has defined three functionally distinct subsets of
antigen-experienced CD8+ T cells based on their dif-
ferential expression of CX3CR1 [331].
Antigen-experienced B cells also use chemokine
receptor switching to direct differentiated cells to dis-
crete tissues or tissue domains. CCR7 up-regulation
directs activated B cells to the boundary of the follicle
and the T-cell area [332]. CXCR4 and CXCR5 are
involved in the movement of antigen-experienced B
cells in germinal centers, and CCR6 expression marks
memory B-cell precursors in these structures [333–335].
CXCR4 homes long-lived plasma cells to supportive
niches in BM and spleen [336,337], and CCR9 and
CCR10 direct plasma cell homing to the intestine and
mammary gland [338–343].
Concluding remarks
The chemokine network is enormously complex, com-
prising of a large number of interacting ligands, recep-
tors, and regulatory proteins engaged in overlapping
and diverse cellular processes. The induction of migra-
tion, particularly of leukocytes, is its central biological
purpose, but its influence extends far beyond this. The
physiological contribution of the chemokine network
is substantial, with fundamental roles in development,
homeostasis, immune surveillance, inflammation, pro-
tection from infection, tissue repair, and innate and
adaptive immunity. Virtually all diseases involve
chemokines and their receptors in some way, some
more prominently than others, and although clinical
translation has been slow, drugs targeting cCKRs have
successfully made it to clinic. The first chemokine was
discovered over 40 years ago, and our understanding
of the chemokines and their receptors is now well
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advanced. Nonetheless, there is still much to uncover,
and chemokines and their receptors are likely to
remain prominent in the scientific literature for years
to come.
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